HOME > 業績 > 2020年




英 文

Ishihara O, Jwa SC, Kuwahara A, Katagiri Y, Kuwabara Y, Hamatani T, Harada M, Ichikawa T
Assisted reproductive technology in Japan: A summary report for 2017 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology.
Reproductive Medicine and Biology 19(1): 3-12, 2020

Ishihara O, Jwa SC, Kuwahara A, Katagiri Y, Kuwabara Y, Hamatani T, Harada M, Osuga Y
Assisted reproductive technology in Japan: A summary report for 2018 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology.
Reprod Med Biol. 2020 Nov 20 doi: 10.1002/rmb2.12358

Ishihara O, Klein BM, Arce JC; Japanese Follitropin Delta Phase 2 Trial Group
Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta.
Fertil Steril. 2020 Nov 30:S0015-0282(20)32631-5. doi: 10.1016/j.fertnstert.2020.10.059. Online ahead of print.

Dyer S, Chambers GM, Adamson GD, Banker M, De Mouzon J, Ishihara O, Kupka M, Mansour R, Zegers-Hochschild F
ART utilization: an indicator of access to infertility care.
Reprod Biomed Online. 41(1):6-9, 2020

de Mouzon J, Chambers GM, Zegers-Hochschild F, Mansour R, Ishihara O, Banker M, Dyer S, Kupka M, Adamson GD
International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology 2012.
Hum Reprod. 35(8): 1900-1913, 2020

Matsuzaki S, Klar M, Mikami M, Shimada M, Grubbs BH, Fujiwara K, Roman LD, Matsuo K
Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence.
Curr Oncol Rep. 22(3):28, 2020

Alvarez Secord A, Bell Burdett K, Owzar K, Tritchler D, Sibley AB, Liu Y, Starr MD, Brady JC, Lankes HA, Hurwitz HI, Mannel RS, Tewari KS, O’Malley DM, Gray H, Bakkum-Gamez JN, Fujiwara K, Boente M, Deng W, Burger RA, Birrer MJ, Nixon AB
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Clin Cancer Res. 26(6):1288-1296, 2020

Fujiwara K, Quinn MA, Coleman RL, Angioli R
Two viral infections in Japan.
Int J Gynecol Cancer. 30(8):1258-1259, 2020

Fujiwara K, Quinn MA
COVID 19 vaccination lessons from Japanese anti-HPV vaccination lobby.
Int J Gynecol Cancer. 2020 Jul 5:ijgc-2020-001712. doi: 10.1136/ijgc-2020-001712. Online ahead of print.

Fujiwara K, Nakayama N, Kato N, Yokosuka O, Tsubouchi H, Takikawa H, Mochida S; Intractable Hepato-Biliary Diseases Study Group of Japan
Infectious complications and timing for liver transplantation in autoimmune acute liver failure in Japan: a subanalysis based on nationwide surveys between 2010 and 2015.
J Gastroenterol. 55(9):888-898, 2020

Ohashi Y, Ikeda M, Kunitoh H, Sasako M, Okusaka T, Mukai H, Fujiwara K, Nakamura M, Oba MS, Kimura T, Ibusuki K, Sakon M
Corrigendum to: Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry.
Jpn J Clin Oncol. 50(11): 1346, 2020

Ohashi Y, Ikeda M, Kunitoh H, Sasako M, Okusaka T, Mukai H, Fujiwara K, Nakamura M, Oba MS, Kimura T, Ibusuki K, Sakon M
Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry.
Jpn J Clin Oncol. 50(11):1246-1253, 2020

Tjokrowidjaja A, Lee CK, Friedlander M, Gebski V, Gladieff L, Ledermann J, Penson R, Oza A, Korach J, Huzarski T, Manso L, Pisano C, Asher R, Lord SJ, Kim SI, Lee JY, Colombo N, Park-Simon TW, Fujiwara K, Sonke G, Vergote I, Kim JW, Pujade-Lauraine E
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
Eur J Cancer. 2020 Nov;139:59-67. doi: 10.1016/j.ejca.2020.08.021. Epub 2020 Sep 23.

Kondo E, Tabata T, Suzuki N, Aoki D, Yahata H, Kotera Y, Tokuyama O, Fujiwara K, Kimura E, Terauchi F, Sumi T, Okamoto A, Yaegashi N, Enomoto T, Sugiyama T
The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG.
J Gynecol Oncol. 2020 Nov;31(6):e94. doi: 10.3802/jgo.2020.31.e94.

Ray-Coquard I, Harter P, Lorusso D, Dalban C, Vergote I, Fujiwara K, Gladieff L, Lück HJ, Floquet A, Chevalier-Place A, Schnelzer A, Pignata S, Selle F, Sehouli J, Brocard F, Mangili G, Pautier P, De Giorgi U, Provansal M, Heudel PE
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial.
JAMA Oncol. 2020 6(12): 1-9, 2020

Yotsumoto J, Sekizawa A, Inoue S, Suzumori N, Samura O, Yamada T, Miura K, Masuzaki H, Sawai H, Murotsuki J, Hamanoue H, Kamei Y, Endo T, Fukushima A, Katagiri Y, Takeshita N, Ogawa M, Nishizawa H, Okamoto Y, Tairaku S, Kaji T, Maeda K, Matsubara K, Ogawa M, Osada H, Ohba T, Kawano Y, Sasaki A, Sago H; Japan NIPT Consortium
Qualitative investigation of the factors that generate ambivalent feelings in women who give birth after receiving negative results from non-invasive prenatal testing.
BMC Pregnancy Childbirth. 20(1):112, 2020

Karino G, Senoo A, Kunikata T, Kamei Y, Yamanouchi H, Nakamura S, Shukuya M, Colman RJ, Koshiba M
Inexpensive Home Infrared Living/Environment Sensor with Regional Thermal Information for Infant Physical and Psychological Development.
Int J Environ Res Public Health. 17(18):6844, 2020

Suzumori N, Sekizawa A, Takeda E, Samura O, Sasaki A, Akaishi R, Wada S, Hamanoue H, Hirahara F, Sawai H, Nakamura H, Yamada T, Miura K, Masuzaki H, Nakayama S, Kamei Y, Namba A, Murotsuki J, Yamaguchi M, Tairaku S, Maeda K, Kaji T, Okamoto Y, Endo M, Ogawa M, Kasai Y, Ichizuka K, Yamada N, Ida A, Miharu N, Kawaguchi S, Hasuo Y, Okazaki T, Ichikawa M, Izumi S, Kuno N, Yotsumoto J, Nishiyama M, Shirato N, Hirose T, Sago H
Retrospective details of false-positive and false-negative results in non-invasive prenatal testing for fetal trisomies 21, 18 and 13.
Eur J Obstet Gynecol Reprod Biol. 2020 Oct 27;256:75-81. doi: 10.1016/j.ejogrb.2020.10.050. Online ahead of print.

Hasegawa J, Wada S, Kasamatsu A, Nakamura M, Hamanoue H, Iwata E, Murotsuki J, Nagai R, Tateishi Y, Sunami R, Tajima A, Murata S, Matsubara K, Nakata M, Kondo A, Nishiyama M, Sasaki A, Sekizawa A, Sago H, Kamei Y
Distribution of PAPP-A and total hCG between 11 and 13 weeks of gestation in Japanese pregnant women.
J Matern Fetal Neonatal Med. 33(12): 2017-2022, 2020

Nishio S, Matsumoto K, Takehara K, Kawamura N, Hasegawa K, Takeshima N, Aoki D, Kamiura S, Arakawa A, Kondo E, Hirakawa T, Yamamoto K, Aoki M, Stein K, Keefe S, Fujiwara K, Ushijima K
Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100.
Cancer Sci. 111(4):1324-1332, 2020

Hasegawa K, Shimada M, Takeuchi S, Fujiwara H, Imai Y, Iwasa N, Wada S, Eguchi H, Oishi T, Sugiyama T, Suzuki M, Nishiyama M, Fujiwara K
A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer.
Br J Cancer. 122(6):766-770, 2020

Ebata T, Yonemori K, Nishikawa T, Sudo K, Shimomura A, Noguchi E, Fujiwara Y, Kato T, Hasegawa K, Fujiwara K, Tamura K
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Oncology. 98(10): 699-705, 2020

Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T, Yabuno A, Nishijima A, Nejo T, Kobayashi Y, Sato S, Ikeda Y, Miyai M, Takahashi Y, Yamaguchi R, Fujiwara K, Aburatani H, Kakimi K
Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
J Immunother Cancer. 2020 May;8(1):e000375. doi: 10.1136/jitc-2019-000375.

Nagasawa S, Ikeda K, Horie-Inoue K, Sato S, Takeda S, Hasegawa K, Inoue S
Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients.
Endocr J. 67(2):219-229, 2020

Gotoh O, Kiyotani K, Chiba T, Sugiyama Y, Takazawa Y, Nemoto K, Kato K, Tanaka N, Nomura H, Hasegawa K, Fujiwara K, Takamatsu S, Matsumura N, Noda T, Mori S
Immunogenomic landscape of gynecologic carcinosarcoma.
Gynecol Oncol. 2020 Dec 6:S0090-8258(20)34158-5. doi: 10.1016/j.ygyno.2020.11.030. Online ahead of print.

Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.
J Gynecol Oncol. 2020 Dec 10. doi: 10.3802/jgo.2021.32.e16. Online ahead of print.

Tabata S, Yamasawa F, Torii S, Manabe T, Kamada H, Namba A, Kato J, Kaneko H, Tahara K, Tsukahara Y, Sato K
Use of nutritional supplements by elite Japanese track and field athletes.
J Int Soc Sports Nutr. 17(1):38, 2020.

Yoshida H, Shintani D, Kawashima N, Fujiwara K
Predicting toxicity of platinum and taxane-based chemotherapy in older patients with gynecologic cancer.
J BUON. 25(2):736-742, 2020

Onuki M, Matsumoto K, Iwata T, Yamamoto K, Aoki Y, Maenohara S, Tsuda N, Kamiura S, Takehara K, Horie K, Tasaka N, Yahata H, Takei Y, Aoki Y, Kato H, Motohara T, Nakamura K, Ishikawa M, Kato T, Yoshida H, Matsumura N, Nakai H, Shigeta S, Takahashi F, Noda K, Yaegashi N, Yoshikawa H
Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan.
Cancer Sci. 111(7):2546-2557, 2020

Jwa SC, Seto S, Takamura M, Kuwahara A, Kajihara T, Ishihara O
Ovarian stimulation increases the risk of ectopic pregnancy for fresh embryo transfers: an analysis of 68,851 clinical pregnancies from the Japanese Assisted Reproductive Technology registry.
Fertil Steril. 114(6): 1198-1206, 2020

Yabuno A, Matsushita H, Hamano T, Tan TZ, Shintani D, Fujieda N, Tan DSP, Huang RY, Fujiwara K, Kakimi K, Hasegawa K
Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma.
Sci Rep. 2020 Oct 28;10(1):18503. doi: 10.1038/s41598-020-75536-1.

Motohashi T, Yabuno A, Michimae H, Ohishi T, Nonaka M, Takano M, Nishio S, Fujiwara H, Fujiwara K, Kondo E, Sugiyama T, Tabata T.
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.
J Gynecol Oncol. 2020 Nov 10. doi: 10.3802/jgo.2021.32.e9. Online ahead of print.

Ikeda Y, Sato S, Yabuno A, Shintani D, Ogasawara A, Miwa M, Zewde M, Miyamoto T, Fujiwara K, Nakamura Y, Hasegawa K
High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo.
J Gynecol Oncol. 2020 Nov;31(6):e93. doi: 10.3802/jgo.2020.31.e93.

Nagasawa S, Ikeda K, Horie-Inoue K, Sato S, Takeda S, Hasegawa K, Inoue S
Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100.
Cancer Sci. 111(4): 1324-1332, 2020

Ogasawara A, Hihara T, Shintani D, Yabuno A, Ikeda Y, Tai K, Fujiwara K, Watanabe K, Hasegawa K
Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Cancer Res Treat. 52(4):1219-1228, 2020

Ogasawara A, Sato S, Hasegawa K
Current and future strategies for treatment of ovarian clear cell carcinoma.
J Obstet Gynaecol Res. 2020 Jun 23. doi: 10.1111/jog.14350. Online ahead of print.

Shintani D, Yoshida H, Yabuno A, Fujiwara K
Tolerability and Efficacy of Bevacizumab Monotherapy in Older Patients With Recurrent Ovarian Cancer.
In Vivo. 34(3):1451-1457, 2020

Shintani D, Hihara T, Ogasawara A, Sato S, Yabuno A, Tai K, Fujiwara K, Watanabe K, Hasegawa K
Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer.
Int J Gynecol Cancer. 30(9):1340-1346, 2020

Saito R, Kajihara T, Takamura M, Tochigi H, Sato T, Ishihara O
High stretch cycling inhibits the morphological and biological decidual process in human endometrial stromal cells.
Reprod Med Biol. 19(4): 378-384, 2020

邦 文

瀬戸さち恵、左 勝則、山口 哲、霞澤 匠、松田尚子、高村将司、難波 聡、梶原 健、岡垣竜吾、石原 理
埼玉産科婦人科学会雑誌50(1): 33-38, 2020


英 文

Tamaru S, Kajihara T, Mizuno Y, Mizuno Y, Tochigi H, Ishihara O
Endometrial microRNAs and their aberrant expression patterns.
Med Mol Morphol . 53(3): 131-140 ,2020

邦 文

石原 理
日本医師会雑誌148(12): 2423-2426, 2020

石原 理
奈良県産婦人科医会誌63: 22-24, 2020

石原 理、山田満稔、米村滋人、加藤和人
年報医事法学35: 36-47, 2020

産科と婦人科87(6): 695-699, 2020

周産期医学50(8): 1322-1323, 2020

Pharma Medica 38(6): 37-39, 2020

更年期と加齢のヘルスケア19(1): 21-25, 2020

梶原 健
日本医師会雑誌148(12): 2390 ,2020

梶原 健、左 勝則、高村将司
【外来でみる子宮内膜症診療-患者特性に応じた管理・投薬のコツ】ライフステージに応じた患者への対応 子宮内膜症をもつ患者に産婦人科処置を行う際には骨盤内感染・卵巣膿瘍に要注意! ART手技を含めて
臨床婦人科産科74(6): 579-583, 2020

【婦人科医が知っておくべきがん遺伝子パネル検査の基礎知識】がん個別化治療への道筋 婦人科がんにおける分子標的治療薬を用いた臨床試験とトランスレーショナルリサーチ
産婦人科の実際69(7): 735-743, 2020
病理と臨床38(7): 625-629, 2020

難波 聡
周産期医学50(8): 1312-1314, 2020

高村将司、石原 理
【やさしくわかる 産科婦人科検査マスターブック】(第3章)生殖内分泌分野 着床前検査(PGT)
産科と婦人科87(Suppl): 293-297, 2020

【子宮内膜症・子宮腺筋症の新たな展開】子宮内膜症・子宮腺筋症の病因・病態 子宮内膜症・子宮腺筋症と免疫異常

田丸俊輔、難波 聡、石原 理
産科と婦人科87(7): 777-781, 2020

黒崎 亮
【エキスパートたちが教える!ワクチン【総整理】】(3章)疾患別のワクチン情報 HPV
jmed mook 68: 124-127, 2020

藪野 彰、長谷川幸清
Gynecologic Cancer 婦人科癌 婦人科癌化学療法2020 子宮頸癌薬物療法の最前線
癌と化学療法47(2): 242-246, 2020